NeuroMetrix, Inc. (NURO) News
Filter NURO News Items
NURO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NURO News Highlights
- For NURO, its 30 day story count is now at 2.
- Over the past 7 days, the trend for NURO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NURO are DEC and DC.
Latest NURO News From Around the Web
Below are the latest news stories about NEUROMETRIX INC that investors may wish to consider to help them evaluate NURO as an investment opportunity.
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)WOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute COVID-19 syndrome (PACS), commonly called Long COVID. The presentation was made at the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP) annual meeting in Washington DC. The trial was conducted at the Baylor College of Medicine in collaboration |
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)WOBURN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of results from a NIH-funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chronic chemotherapy-induced peripheral neuropathy (CIPN): a proof-of-concept randomized clinical trial." The paper has been electronically published in The Journal of Pain. The study was a phase 2, multi-site, double blinded, randomized, sham-controlled trial. A total of 142 |
NeuroMetrix Announces One-for-Eight Reverse Stock SplitWOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the “Effective Time”). The shares underlying the Company's outstanding options will also be adjusted accordingly. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued lis |
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register NowMIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting |
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023WOBURN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023. This live, interactive, online event will give shareholders and the investment community the opportunity to interact in real time with the Company’s Chairman and Chief Executive Officer, Dr. Shai N. Gozani. Dr. Gozani will provide a brief update on business highlights and recent developments, including the evolut |
NeuroMetrix, Inc. (NASDAQ:NURO) Q3 2023 Earnings Call TranscriptNeuroMetrix, Inc. (NASDAQ:NURO) Q3 2023 Earnings Call Transcript October 27, 2023 Operator: Good morning, and welcome to NeuroMetrix Third Quarter 2023 Business and Financial Highlights Update. My name is Norma, and I’ll be your moderator on the call. On this call, the company may make statements which are not historical facts and are considered forward-looking […] |
Q3 2023 NeuroMetrix Inc Earnings CallQ3 2023 NeuroMetrix Inc Earnings Call |
NeuroMetrix Reports Q3 2023 Business HighlightsWOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "We continue to be encouraged by the market response to Quell® Fibromyalgia during its strategic launch. We now have field sales capabilities in the key markets of T |
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference CallWOBURN, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on October 26, 2023. For participants who wish to access the Q3 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN wi |
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register NowMIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting |